Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 16.76 EUR Market Closed
Market Cap: 490.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Medincell SA
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Medincell SA
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
Medincell SA
PAR:MEDCL
Accumulated Depreciation
-€5.4m
CAGR 3-Years
-21%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Sanofi SA
PAR:SAN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Accumulated Depreciation
-€586.1m
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Vetoquinol SA
PAR:VETO
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Virbac SA
PAR:VIRP
Accumulated Depreciation
-€471.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Accumulated Depreciation
-€11.1m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Medincell SA
Glance View

Market Cap
487.2m EUR
Industry
Pharmaceuticals

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

MEDCL Intrinsic Value
21.71 EUR
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Medincell SA's Accumulated Depreciation?
Accumulated Depreciation
-5.4m EUR

Based on the financial report for Mar 31, 2024, Medincell SA's Accumulated Depreciation amounts to -5.4m EUR.

What is Medincell SA's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
-24%

Over the last year, the Accumulated Depreciation growth was -17%. The average annual Accumulated Depreciation growth rates for Medincell SA have been -21% over the past three years , -24% over the past five years .

Back to Top